Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

RPRX Royalty Pharma plc

Price (delayed)

$34.84

Market cap

$19.59B

P/E Ratio

14.11

Dividend/share

$0.86

EPS

$2.47

Enterprise value

$26.12B

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals ...

Highlights
Royalty Pharma's EPS has increased by 38% YoY and by 29% QoQ
The net income has grown by 37% YoY and by 27% from the previous quarter
The company's quick ratio has shrunk by 88% YoY but it rose by 9% QoQ
The P/E is 71% lower than the 5-year quarterly average of 49.0 but 3.8% higher than the last 4 quarters average of 13.6
Royalty Pharma's debt has increased by 24% YoY
RPRX's equity is down by 5% since the previous quarter

Key stats

What are the main financial stats of RPRX
Market
Shares outstanding
562.24M
Market cap
$19.59B
Enterprise value
$26.12B
Valuations
Price to earnings (P/E)
14.11
Price to book (P/B)
2.05
Price to sales (P/S)
6.7
EV/EBIT
19.5
EV/EBITDA
19.5
EV/Sales
11.54
Earnings
Revenue
$2.26B
Gross profit
$2.26B
Operating income
$1.9B
Net income
$1.09B
EBIT
$1.34B
EBITDA
$1.34B
Free cash flow
$2.58B
Per share
EPS
$2.47
EPS diluted
$2.46
Free cash flow per share
$5.91
Book value per share
$16.98
Revenue per share
$5.2
TBVPS
$40.43
Balance sheet
Total assets
$17.61B
Total liabilities
$7.82B
Debt
$7.62B
Equity
$9.79B
Working capital
$660.39M
Liquidity
Debt to equity
0.78
Current ratio
1.56
Quick ratio
1.56
Net debt/EBITDA
4.88
Margins
EBITDA margin
59.2%
Gross margin
100%
Net margin
48.3%
Operating margin
83.9%
Efficiency
Return on assets
6.1%
Return on equity
10.9%
Return on invested capital
5.7%
Return on capital employed
8.2%
Return on sales
59.2%
Dividend
Dividend yield
2.47%
DPS
$0.86
Payout ratio
34.8%

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
-1.22%
1 week
3.14%
1 month
6.15%
1 year
28.09%
YTD
36.57%
QTD
11.92%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.26B
Gross profit
$2.26B
Operating income
$1.9B
Net income
$1.09B
Gross margin
100%
Net margin
48.3%

RPRX financials

The operating income has soared by 102% YoY and by 47% from the previous quarter
The operating margin has surged by 100% year-on-year and by 47% since the previous quarter
The net income has grown by 37% YoY and by 27% from the previous quarter
Royalty Pharma's net margin has increased by 35% YoY and by 27% QoQ

Price vs fundamentals

How does RPRX's price correlate with its fundamentals

RPRX Price vs fundamentals

RPRX Earnings waterfall

RPRX Price vs fair value

Growth

What is Royalty Pharma's growth rate over time

RPRX growth chart

Valuation

What is Royalty Pharma stock price valuation
P/E
14.11
P/B
2.05
P/S
6.7
EV/EBIT
19.5
EV/EBITDA
19.5
EV/Sales
11.54

Valuation vs average

Price to earnings (P/E)

The P/E is 71% lower than the 5-year quarterly average of 49.0 but 3.8% higher than the last 4 quarters average of 13.6
Royalty Pharma's EPS has increased by 38% YoY and by 29% QoQ

Price to book (P/B)

RPRX's P/B is 28% above its last 4 quarters average of 1.6 but 18% below its 5-year quarterly average of 2.5
RPRX's equity is down by 5% since the previous quarter

Price to sales (P/S)

The P/S is 22% above the last 4 quarters average of 5.5 but 2.9% below the 5-year quarterly average of 6.9

Efficiency

How efficient is Royalty Pharma business performance
RPRX's ROE is up by 35% YoY and by 28% from the previous quarter
Royalty Pharma's return on sales has increased by 35% YoY and by 24% QoQ
The ROA has increased by 24% from the previous quarter and by 24% YoY
The ROIC is up by 24% YoY and by 21% QoQ

Dividends

What is RPRX's dividend history
DPS
$0.86
Dividend yield
2.47%
Payout ratio
34.8%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Royalty Pharma financials performed over time

Assets vs liabilities

Royalty Pharma's total assets is 125% more than its total liabilities
The company's quick ratio has shrunk by 88% YoY but it rose by 9% QoQ
The current ratio has dropped by 88% year-on-year but it has increased by 8% since the previous quarter

Debt vs equity

Royalty Pharma's debt is 22% lower than its equity
The debt to equity has increased by 26% YoY and by 5% QoQ
Royalty Pharma's debt has increased by 24% YoY

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.